Joanne Jiang Chen

China Nuokang Bio-Pharmaceutical, Inc. is a biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. It currently sells a portfolio of fourteen products, including three principal products: Baquting, its flagship bleeding control product; Aiduo, its cardiovascular stress imaging agent; and Aiwen, its anti-arrhythmic agent. The company has also entered into an exclusive agreement for the marketing and distribution in China of Kaitong, an intravenous injectable lipid emulsion of vasodilator alprostadil for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis. Its product pipeline includes four product candidates under development that address the growing market and medical needs for hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. The company was founded on November 1997 and is headquartered in Shenyang, China.

HBM BioMed China Partners Ltd. is a venture capital fund focused on biomedical investments in companies based in China.

Part of ClinChoice Medical (TIANJIN) Co., Ltd., Fountain Medical Development Ltd. is a clinical CRO that provides one-stop services for biomedical and medical equipment customers. Clinchoice has been accelerating drug and device approvals to market for more than 25 years and offers services such as project management, clinical operations, biological statistics, data management, registered affairs, medical affairs, and drug warning. The quality service runs through every link of the Clinchoice Kunyu service, and the quality assurance team is an independent team that focuses on the construction and continuous improvement of the American company's internal quality management system. The company was founded by Dan Zhang and Ling Zhen has been the CEO of the company since 2020. Laibiyi was founded in 2016 and is committed to solving the pain points of clinical research through in-depth cooperation with hospitals and a clinical research center that builds standardized standards. In 2021, Clinchoice Kunzhe acquired Laibiyi Technology (Xiamen) Co., Ltd. to further improve its phase I clinical trial platform.